Gene Therapy in Oncology – Thematic Research
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Gene Therapy Market
Gene therapy is the introduction of exogenous, genetic material into cells to treat a disease. Gene therapies provide therapeutic benefits to patients, especially those suffering from monogenic diseases. Cancers are generally not monogenic in origin, so gene therapies are more likely to be used to treat cancer by modifying gene regulation in tumorigenic pathways and expressing genes in cells that cause them to be recognized as foreign, or to elicit an immune response to tumorigenic cells.
Sales of products that comprise the categories of in vivo gene therapy are forecast to reach over $7B by 2027. The market for gene therapies, especially those using viral vectors, is expected to be slowed down by the high cost of therapies.
Gene Therapy Market Value by Class
For more insights on the gene therapy market value, download a free report sample.
Gene Therapy in Oncology: Trends and Opportunities
The viral vector gene therapy field is expanding, but the high cost is an issue. However, the non-viral vector field is hindered by the inefficient delivery of transgenes. China’s Gendicine is the only in vivo viral gene therapy that is approved for cancer treatment. Insertional oncogenesis remains a constant concern after the death of a patient in 1999 from adenoviral-based Advexin. Current reimbursement programs struggle to cover the high cost of viral gene therapies, so new models are being considered.
There is a bigger window to manipulate non-viral vectors to improve stability and reduce transgene degradation before it reaches tumor cells. Non-viral vectors are viewed as safe because is lower immunogenicity compared to the use of viral vectors. When using viral technology, patients must be pre-screened for pre-existing immunity to certain viral strains. There is no need to do that when using non-viral vectors.
Gene Therapy in Oncology: Value Chain
The gene therapy in the oncology value chain consists of gene therapy vectors, therapeutic oligonucleotides, genome editing, and oncolytic viruses.
Therapeutic oligonucleotides: They are strands of DNA or RNA that either bind to receptors to stimulate an immune response or bind to RNA sequences to inhibit the translation of an oncogenic protein, or to indirectly promote the expression of a tumor suppressing protein.
Gene Therapy in Oncology Value Chain Analysis
For more insights on the gene therapy in oncology value chains, download a free report sample
Marketed Gene Therapy in Oncology Products in the 8MM by Types
Viral GT and oncolytic virus are the key types of marketed gene therapy in oncology products in the 8MM based on type. Oncolytic virus has the maximum number of marketed gene therapy in oncology products.
Marketed Gene Therapy in Oncology Products Analysis by Types
For more insights on the marketed gene therapy in oncology products by types, download a free report sample
Marketed Gene Therapy in Oncology Products in the 8MM by Therapy Areas
Head and neck cancers (HNCS), malignant pleural effusion, metastatic liver cancer, and metastatic melanoma are some of the leading therapy areas in the marketed gene therapy in oncology products in the 8MM. Head and neck cancer (HNCS) has the majority number of marketed products in terms of the number of approved agents.
Marketed Gene Therapy in Oncology Products Analysis by Therapy Areas
For more insights on the marketed gene therapy in oncology products by therapy areas, download a free report sample
Gene Therapy in Oncology Pipeline Products in the 8MM by Types
Oncolytic virus, therapeutic oligonucleotide, viral vector, non-viral vector, and genome editing are the key types of gene therapy in oncology pipeline products. Oncolytic virus has the maximum number of pipeline products.
Gene Therapy in Oncology Pipeline Products Analysis by Types
For more insights on the gene therapy in oncology pipeline products by types, download a free report sample
Gene Therapy in Oncology Pipeline Products in the 8MM by Therapy Areas
Various solid tumors, melanoma, pancreatic cancer, ovarian cancer, triple-negative breast cancer (TNBC), and hepatocellular carcinoma are some of the leading therapy areas in the gene therapy in oncology pipeline products. Various solid tumors have the majority number of pipeline products.
Gene therapy in Oncology Pipeline Products Analysis by Therapy Areas
For more insights on the gene therapy in Oncology pipeline products by therapy areas, download a free report sample
Leading Gene Therapy Companies in Oncology
Some of the leading companies making their mark within the gene therapy in oncology theme are Amgen, SIBIono, Sunway Biotech, Candel, and CG Oncology.
Amgen: It is a biotechnology company that discovers, develops, manufactures, and markets innovative human therapeutics to treat patients suffering from serious diseases. It develops novel medicines in six focused therapeutic areas, including cardiovascular disease, oncology/hematology, inflammation, bone health, neuroscience, and nephrology. The company develops products by using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels such as print, television, and online media. Amgen is headquartered in Thousand Oaks, California, US.
Gene Therapy in Oncology Report Overview
Report Pages | 104 |
Regions Covered | Global |
Key Trends | Industry Trends and Regulatory Trends |
Value Chains | Gene Therapy Vectors, Therapeutic Oligonucleotides, Genome Editing, and Oncolytic Viruses |
Key Types (Marketed Products) | Viral GT and Oncolytic Virus |
Key Therapy Areas (Marketed Products) | Head And Neck Cancers (HNCS), Malignant Pleural Effusion, Metastatic Liver Cancer, and Metastatic Melanoma |
Key Types (Pipeline Products) | Oncolytic Virus, Therapeutic Oligonucleotide, Viral Vector, Non-Viral Vector, and Genome Editing |
Key Therapy Areas (Pipeline Products) | Various Solid Tumors, Melanoma, Pancreatic Cancer, Ovarian Cancer, Triple-Negative Breast Cancer (TNBC), and Hepatocellular Carcinoma |
Gene therapy Companies in Oncology | Amgen, Sibiono, Sunway Biotech, Candel, and CG Oncology |
Scope:
- Overview of gene therapy including classification of therapy and technologies, regulatory and market access details, product & company profiles.
- Quotes from US- and 5EU-based key opinion leaders and researchers.
- Key topics covered for gene therapy in oncology in the 8MM include trends, value chain, market analysis, opportunities, challenges and unmet needs and high-value deals.
- Pipeline analysis: Comprehensive data split across different phases and indications, emerging novel trends under development, and analysis of the most promising late-stage pipeline drugs for classes of gene therapy (Phase III and pre-registration).
- Analysis of the key dynamics of the gene therapy market. Insightful review of the key industry drivers and challenges. Deals and R&D strategies covered in detail to highlight business opportunities.
Key questions answered:
- What are the late-stage gene therapy pipeline agents in development for cancer? Which class of gene therapy drugs will have the highest peak sales, and why?
- What are the current unmet needs that gene therapies can address in the treatment of cancer? What are the opportunities for R&D?
- How is the field of gene therapy going to move forward? Which technologies are the most promising for combinations?
- What is the regulatory landscape for gene therapies in the US, the 5EU, Japan and China?
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current deals and technologies to identify companies with the highest potential.
- Develop business strategies by understanding the trends shaping and driving the global oncology gene therapy market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global oncology gene therapy market in the future.
- Design your development strategy through a review of potential novel targets or combinations across indications.
- Understand the challenges and strategies impacting the development of oncology gene therapy agents in preclinical studies and clinical trials.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the classes of gene therapy and indications that present maximum opportunities for consolidations, investments and strategic partnerships.
SiBiono
Sunway Biotech
Candel
CG Oncology
Checkmate
Daiichi Sankyo
Ferring
FKD
Geron
Idera
Istari
VBL
Table of Contents
Frequently asked questions
-
What are the key types in the marketed gene therapy in oncology products in the 8MM?
Viral GT and oncolytic virus are the key types of marketed gene therapy in oncology products in the 8MM.
-
What are the key therapy areas in the marketed gene therapy in oncology products in the 8MM?
Head and neck cancers (HNCS), malignant pleural effusion, metastatic liver cancer, and metastatic melanoma are some of the leading therapy areas in the marketed gene therapy in oncology products market in the 8MM.
-
What are the key types in the gene therapy in oncology pipeline products in the 8MM?
Oncolytic virus, therapeutic oligonucleotide, viral vector, non-viral vector, and genome editing are the key types of gene therapy in oncology pipeline products in the 8MM.
-
What are the key therapy areas in the gene therapy in oncology pipeline products in the 8MM?
Various solid tumors, melanoma, pancreatic cancer, ovarian cancer, triple-negative breast cancer (TNBC), and hepatocellular carcinoma are some of the leading therapy areas in the gene therapy in oncology pipeline products in the 8MM.
-
Which are the leading companies in the gene therapy in oncology marketed and pipeline products market?
Some of the leading companies making their mark within the gene therapy in oncology theme are Amgen, SIBIono, Sunway Biotech, Candel, and CG Oncology.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.